BCR/ABL - PHILADELPHIA CHROMOSOME - QUALITATIVE (BREAKPOINT ANALYSIS) - PCR

BCR/ABL - Philadelphia Chromosome - Qualitative (Breakpoint Analysis) - PCR is an advanced molecular diagnostic test used to detect the presence of the BCR-ABL fusion gene resulting from the Philadelphia chromosome abnormality. The test identifies specific breakpoint regions involved in the chromosomal translocation between chromosomes 9 and 22, which is strongly associated with Chronic Myeloid Leukemia (CML) and certain forms of Acute Lymphoblastic Leukemia (ALL).

This qualitative PCR assay helps determine whether the BCR-ABL fusion transcript is present in a patient's sample. Detection of the fusion gene plays a crucial role in confirming diagnosis, classifying leukemia subtypes, and guiding targeted treatment decisions.

Benefits of the Test

• Accurately detects the BCR-ABL fusion gene.
• Identifies Philadelphia chromosome-associated leukemia.
• Supports diagnosis of Chronic Myeloid Leukemia (CML).
• Helps classify leukemia subtypes.
• Provides rapid molecular confirmation.
• Assists in treatment planning and risk assessment.
• Identifies specific BCR-ABL transcript variants.
• Supports precision oncology and targeted therapy decisions.

Why Doctors Recommend This Test

Doctors recommend this test for patients with suspected Chronic Myeloid Leukemia (CML), Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL), unexplained abnormal blood counts, bone marrow abnormalities, or suspected hematological malignancies. The test is frequently used as an initial molecular diagnostic investigation to confirm the presence of the BCR-ABL fusion gene.

Detection of specific breakpoint transcripts helps physicians establish an accurate diagnosis and determine appropriate treatment strategies.

Preparation Before Test

• No fasting is generally required.
• A peripheral blood sample or bone marrow specimen may be collected.
• Inform your doctor about ongoing cancer treatments.
• Provide previous laboratory and genetic test reports if available.
• Follow all sample collection instructions carefully.
• Ensure prompt transportation of the specimen to the laboratory.

Normal Reporting Time

Most BCR/ABL - Philadelphia Chromosome - Qualitative (Breakpoint Analysis) - PCR reports at Focus Diagnostics are available within 2–3 hours for specimen processing and molecular workflow initiation. Final PCR analysis and interpretation are typically completed within a few working days depending on laboratory protocols.

Who Should Take This Test?

This test may be recommended for:

• Patients with suspected Chronic Myeloid Leukemia (CML).
• Individuals with Philadelphia chromosome-positive leukemia suspicion.
• Patients with unexplained elevated white blood cell counts.
• Individuals undergoing leukemia evaluation.
• Patients with abnormal bone marrow findings.
• People requiring molecular confirmation of leukemia.
• Individuals being assessed for targeted therapy eligibility.
• Patients with suspected hematological malignancies.

Detailed Information

The Philadelphia chromosome is one of the most significant genetic abnormalities identified in hematologic cancers. It is formed through a reciprocal translocation between chromosome 9 and chromosome 22, designated as t(9;22)(q34;q11). This translocation results in fusion of the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9, creating the BCR-ABL fusion gene.

The BCR-ABL fusion gene encodes an abnormal tyrosine kinase protein that continuously stimulates uncontrolled growth and survival of leukemic cells. This molecular abnormality is present in approximately 95% of patients with Chronic Myeloid Leukemia (CML) and in a subset of patients with Acute Lymphoblastic Leukemia (ALL).

BCR/ABL - Philadelphia Chromosome - Qualitative (Breakpoint Analysis) - PCR utilizes highly sensitive Polymerase Chain Reaction technology to detect the presence of BCR-ABL fusion transcripts in patient samples. Unlike quantitative testing, which measures transcript levels, this qualitative assay focuses on identifying whether the fusion gene is present and determining the specific breakpoint transcript type.

Different BCR-ABL transcript variants may occur depending on the breakpoint location within the BCR gene. Common transcript types include p190, p210, and p230 variants. Identification of the transcript type is important because it may have diagnostic, prognostic, and therapeutic significance.

The test plays a critical role in confirming the diagnosis of Philadelphia chromosome-positive leukemia and helping clinicians select targeted therapies such as tyrosine kinase inhibitors (TKIs). Molecular confirmation of BCR-ABL positivity is considered a key step in modern leukemia management.

Results are interpreted alongside clinical findings, complete blood counts, bone marrow examination results, cytogenetic studies, and other molecular investigations. Positive findings may lead to additional quantitative monitoring tests for treatment response assessment.

At Focus Diagnostics, BCR/ABL - Philadelphia Chromosome - Qualitative (Breakpoint Analysis) - PCR testing is performed using advanced molecular diagnostic platforms, highly sensitive PCR technology, and stringent quality assurance procedures to provide accurate, reliable, and clinically meaningful diagnostic results.